Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116936314 | 11693631 | 4 | F | 20160912 | 20151103 | 20160914 | EXP | US-PFIZER INC-2015368815 | PFIZER | 69.00 | YR | F | Y | 0.00000 | 20160914 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116936314 | 11693631 | 1 | PS | XELJANZ | TOFACITINIB CITRATE | 1 | 5 MG, 2X/DAY | M39801 | 203214 | 5 | MG | TABLET | BID | ||||||
| 116936314 | 11693631 | 2 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | 203214 | TABLET | |||||||||||
| 116936314 | 11693631 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | UNK | 11719 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 116936314 | 11693631 | 1 | Rheumatoid arthritis |
| 116936314 | 11693631 | 2 | Arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 116936314 | 11693631 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 116936314 | 11693631 | Bullous lung disease | |
| 116936314 | 11693631 | Chronic obstructive pulmonary disease | |
| 116936314 | 11693631 | Condition aggravated | |
| 116936314 | 11693631 | Cough | |
| 116936314 | 11693631 | Middle ear effusion | |
| 116936314 | 11693631 | Sinusitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |